Condition
Hemophilia B Without Inhibitor
Total Trials
4
Recruiting
0
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Early P 1 (2)
P 1 (1)
P 3 (1)
Trial Status
Unknown2
Active Not Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06569108Phase 3Active Not Recruiting
Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors
NCT06125756Early Phase 1UnknownPrimary
Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001
NCT06119659Early Phase 1UnknownPrimary
Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001
NCT04072237Phase 1Completed
Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia
Showing all 4 trials